Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review.
EGFR
T790M
non-small cell lung cancer
osimertinib
squamous cell carcinoma of the lung
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
03
08
2023
received:
05
07
2023
accepted:
05
08
2023
medline:
3
10
2023
pubmed:
29
8
2023
entrez:
29
8
2023
Statut:
ppublish
Résumé
Among epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancers, squamous cell carcinoma is less common and shows lower responsiveness to first-generation EGFR tyrosine kinase inhibitors (TKIs) compared to adenocarcinoma. However, the efficacy of osimertinib for squamous cell carcinoma with EGFR mutations is not well known. This study reports the case of a 57-year-old male diagnosed as having stage IIIC squamous cell lung cancer. Oncomine Dx Target Test identified EGFR exon19 deletion and de novo EGFR T790M mutation with variant allele frequencies (VAF) of 21.6% and 25.2%, respectively. The patient was treated with osimertinib after progression on chemoradiotherapy followed by durvalumab, and a partial response was maintained for more than 20 months. To predict EGFR-TKI efficacy, confirmation of gene mutations and VAF using next-generation sequencing is helpful.
Identifiants
pubmed: 37641467
doi: 10.1111/1759-7714.15081
pmc: PMC10542461
doi:
Substances chimiques
osimertinib
3C06JJ0Z2O
ErbB Receptors
EC 2.7.10.1
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
EGFR protein, human
EC 2.7.10.1
Types de publication
Review
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
2886-2889Informations de copyright
© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Thorac Cancer. 2020 Sep;11(9):2704-2708
pubmed: 32667739
Thorac Cancer. 2023 Oct;14(28):2886-2889
pubmed: 37641467
Clin Lung Cancer. 2016 Jul;17(4):309-14
pubmed: 26725853
Mol Clin Oncol. 2019 Aug;11(2):127-131
pubmed: 31316771
Cells. 2021 Nov 16;10(11):
pubmed: 34831415
Onco Targets Ther. 2017 Mar 28;10:1859-1863
pubmed: 28405166
J Thorac Oncol. 2013 Jan;8(1):89-95
pubmed: 23242440
J Thorac Oncol. 2017 Oct;12(10):e167-e169
pubmed: 28939151
J Thorac Oncol. 2018 Dec;13(12):e252-e254
pubmed: 30467047
Lung Cancer. 2020 Feb;140:113-115
pubmed: 31810534
J Med Chem. 2014 Oct 23;57(20):8249-67
pubmed: 25271963
Clin Lung Cancer. 2018 Jan;19(1):e63-e66
pubmed: 29126779
Intern Med. 2021 Apr 1;60(7):1067-1071
pubmed: 33132329
Curr Oncol. 2022 May 13;29(5):3531-3539
pubmed: 35621675
Thorac Cancer. 2023 Mar;14(7):709-713
pubmed: 36710365
Oncotarget. 2017 Jul 25;8(30):49680-49688
pubmed: 28591695
Transl Lung Cancer Res. 2021 Feb;10(2):662-674
pubmed: 33718012
Oncol Lett. 2017 Nov;14(5):5947-5951
pubmed: 29113230
Ann Transl Med. 2019 Jan;7(1):14
pubmed: 30788361